The FDA has approved the first time ever that a treatment can restore the voice of a person suffering from Recurrent respiratory papillomatosis (RRP), a rare disease that can silence a person's voice and breath. The only treatment available was repeated surgery. The new immunotherapy, Papzimeos, involves four injections over 12 weeks and less than half of patients no longer required surgeries in the year following treatment. This treatment could potentially prevent future infections of R.